NeuroPace (NPCE) Asset Writedowns and Impairment (2020 - 2026)

NeuroPace's Asset Writedowns and Impairment history runs 7 years deep, the most recent figure standing at $76000.0 for Q1 2026.

• In Q1 2026, Asset Writedowns and Impairment rose 72.73% year-over-year to $76000.0; the TTM figure through Mar 2026 stood at $232000.0 (down 6.45% YoY), while the FY2025 annual figure was $200000.0, down 20.32% from the prior year.
• Asset Writedowns and Impairment was $76000.0 for Q1 2026 at NeuroPace, up from $60000.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $107000.0 in Q3 2024 to a low of -$4000.0 in Q4 2022.
• Historically, Asset Writedowns and Impairment has averaged $54294.1 across 5 years, with a median of $49000.0 in 2025.
• The sharpest annual moves came in 2022 and 2023: Asset Writedowns and Impairment sank 107.02% in 2022, then soared 1700.0% in 2023.
• A 5-year view of Asset Writedowns and Impairment shows it stood at -$4000.0 in 2022, then jumped by 1700.0% to $64000.0 in 2023, then slipped by 14.06% to $55000.0 in 2024, then rose by 9.09% to $60000.0 in 2025, then rose by 26.67% to $76000.0 in 2026.
• The last three Asset Writedowns and Impairment figures came in at $76000.0 (Q1 2026), $60000.0 (Q4 2025), and $47000.0 (Q3 2025), per Business Quant data.